Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals Inc.

WSW, NY, July 23rd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) announced this morning that ciprocopan (NXP100) has been approved by China’s Na...

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Re...

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)

Crinetics Pharmaceuticals ( ($CRNX) ) has provided an announcement. On July 6, 2026, Crinetics Pharmaceuticals entered into a Merger Agreement unde...

Crinetics Pharmaceuticals Announces Merger Agreement With Vertex

Crinetics Pharmaceuticals received a Hold rating and price target from TD Cowen analyst Tyler Van Buren today. Van Buren covers the Healthcare sect...

Crinetics Pharmaceuticals (CRNX) Receives a New Rating from a Top Analyst

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atai Beckley N.V. (ATAI), Bioventus (BVS) and Crin...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (ATAI), Bioventus (BVS) and Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals ($CRNX) stock surged nearly 100% in pre-market trading on Tuesday after Vertex Pharmaceuticals ($VRTX) agreed to acquire ...

Why Is Crinetics Stock (CRNX) Surging Nearly 100% in Pre-Market Today, 7/7/26? Analysts React

An announcement from Crinetics Pharmaceuticals ( ($CRNX) ) is now available. On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals ...

Vertex to Acquire Crinetics in $10 Billion Merger

Vertex Pharmaceuticals ($VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker Crinetics Pharmaceutic...

M&A News: Vertex Stock (VRTX) Slips After Announcing the $10B Crinetics Acquisition

Analysts are intrested in these 5 stocks: ( ($DLO) ), ( ($CYPH) ), ( ($BCE) ), ( ($LAC) ) and ( ($CRNX) ). Here is a breakdown of their recent


DLocal, Cypherpunk, BCE, LAC, Crinetics: Trending By Analysts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Crinetics Pharmaceuticals (CRNX) and Definium Therap...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRNX	$83.86	+0.01%	2.32M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRNX	$83.86	+0.0%	2.32M
3
4
5
6

CRNX

CRNX

Get Crinetics Pharmaceuticals Inc. Data in Excel

Get Crinetics Pharmaceuticals Inc. Data in Excel